Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 4,000
- Avg volume
- —
- Day's range
- $1.80 – $1.80
- Shares out
- —
- Stochastic %K
- —
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
Artrya Limited, a medical technology company, engages in the development and commercialization of artificial intelligence platform that detects, diagnoses, and address coronary artery disease in Australia. It offers Salix, a suite of cloud-based software that uses artificial intelligence to automate the detection of coronary artery disease from coronary computed tomography angiography scans to identify and manage pat...
Show more
Artrya Limited, a medical technology company, engages in the development and commercialization of artificial intelligence platform that detects, diagnoses, and address coronary artery disease in Australia. It offers Salix, a suite of cloud-based software that uses artificial intelligence to automate the detection of coronary artery disease from coronary computed tomography angiography scans to identify and manage patients at risk of a heart attack. The company was incorporated in 2018 and is based in West Perth, Australia.
- Industry
- Health Information Services
- Sector
- Healthcare
- Phone
- 61 8 6478 7816
- Website
- https://www.artrya.com
- Address
- 1257 Hay Street, West Perth, Australia
Latest news
No headlines yet.
